GLP-1 Telehealth and Mental Health: What Prescribers Should Screen For

GLP-1 medications don't just affect your weight and metabolism — they affect your brain. The GLP-1 receptor is expressed in brain regions that govern appetite, reward, mood, and emotional regulation. Clinical trials have documented psychiatric adverse events including anxiety, depression, and suicidal ideation as rare but documented side effects. The FDA prescribing information for both semaglutide and tirzepatide includes warnings about psychiatric effects. Here's what GLP-1 telehealth platforms should be screening for — and what most aren't.

What the FDA Warns About

The prescribing information for oral semaglutide (Foundayo's class) includes warnings for suicidal behavior and ideation. The FDA has required Eli Lilly to conduct post-marketing studies on Foundayo's heart, liver, and psychiatric effects. While large-scale clinical trials have not shown a statistically significant increase in suicidal events compared to placebo, the FDA considers the signal important enough to warrant monitoring and disclosure.

Beyond the formal warnings, clinicians who prescribe GLP-1 medications routinely observe mood changes in patients — both positive (improved self-image, reduced food-related anxiety, better sleep from weight loss and reduced sleep apnea) and occasionally negative (mood instability during rapid weight loss, body dysmorphia as physical appearance changes quickly, grief over the loss of food as an emotional coping mechanism).

What Should Be Screened

History of eating disorders. GLP-1 medications dramatically alter the relationship with food — reducing appetite, changing food preferences, and making it physically difficult to overeat. For patients with a history of restrictive eating disorders (anorexia nervosa, ARFID), the appetite suppression may reinforce disordered patterns. For patients with binge eating disorder, GLP-1 medications may be therapeutic — reducing binge urges — but should be prescribed with awareness of the eating disorder history.

Current depression or anxiety. Patients with active depression should be monitored for mood changes during GLP-1 treatment. Rapid weight loss can trigger emotional turbulence even in patients without pre-existing mental health conditions. For patients already managing depression, the added variable of a medication that affects brain reward circuits warrants closer follow-up.

History of suicidal ideation. Per FDA guidance, prescribers should screen for and monitor suicidal thoughts in patients taking GLP-1 medications. This doesn't mean the medication commonly causes suicidal ideation — it means the screening is a safety standard given the class-level FDA warning.

Relationship with food and body image. Losing 15–20% of body weight changes how you look, how others treat you, and how you relate to food. These changes are overwhelmingly positive for most patients, but they can be psychologically complex. A patient who has been overweight for decades may experience unexpected emotions about their new body — including anxiety about maintaining the loss, difficulty accepting compliments, or complicated feelings about being treated differently.

What Most Platforms Get Wrong

The gap between what should be screened and what is screened is significant. Most GLP-1 telehealth platforms ask basic intake questions about depression and anxiety (often a simple yes/no checkbox), but few conduct structured mental health screening, ask about eating disorder history in detail, or have protocols for ongoing psychiatric monitoring during treatment.

This isn't necessarily malicious — it reflects the platform's clinical model. A high-volume prescribing operation optimized for speed doesn't have the clinical infrastructure for nuanced mental health assessment. But it's a gap that matters, especially for the subset of patients who are most vulnerable.

What You Can Do

Be honest on the intake. If you have a history of eating disorders, depression, anxiety, or suicidal ideation, disclose it. The prescriber needs this information to provide safe care — and withholding it to avoid being screened out puts you at risk.

Monitor your own mood. During the first 3 months of GLP-1 treatment, pay attention to mood changes — increased anxiety, persistent sadness, loss of interest in activities, or intrusive thoughts. These may or may not be related to the medication, but they warrant a conversation with your prescriber.

Keep your mental health provider informed. If you see a therapist, psychiatrist, or counselor, tell them you're starting GLP-1 medication. They can provide an additional monitoring layer that your telehealth platform may not offer.

Don't use GLP-1 medication as a substitute for addressing disordered eating. If food restriction, binge-purge cycles, or compulsive exercise are part of your history, GLP-1 medication should be prescribed alongside — not instead of — eating disorder treatment.

Platforms with More Comprehensive Screening

Found Health includes behavioral health support as part of its integrated care model — a meaningful differentiator for patients with mental health considerations alongside weight management.